恶拉戈利治疗子宫内膜异位症的研究进展

Research progress of elagolix in the treatment of endometriosis

子宫内膜异位症常发生于生育期女性,是一种依赖于雌、孕激素调节的妇科疾病,目前主要通过手术及激素类药物长期综合治疗以期改善患者临床症状和减少疾病复发。恶拉戈利(Elagolix)是首个治疗中重度子宫内膜异位症的口服非肽类小分子促性腺激素释放激素受体拮抗剂。本文将对恶拉戈利治疗子宫内膜异位症的机制、临床应用、注意事项及不良反应展开综述。

Endometriosis is a gynecologic disease of reproductive women that relies on estrogen and progesterone regulation.At present,surgery and long-term hormone therapy are mainly used to improve patients′clinical symptoms and reduce disease recurrence.Elagolix is the first oral non-peptide small molecule gonadotropin releasing hormone receptor antagonist for the treatment of moderate to severe endometriosis.The mechanism,clinical application,points to note and side effects of endometriosis are reviewed in this article.